Skip to Content

Vidaza Approval History

FDA Approved: Yes (First approved May 19, 2004)
Brand name: Vidaza
Generic name: azacitidine
Dosage form: for Injectable Suspension
Company: Pharmion Corporation
Treatment for: Myelodysplastic Diseases

Vidaza (azacitidine) is an antineoplastic agent for the treatment of patients with myelodysplastic syndromes.

Development History and FDA Approval Process for Vidaza

DateArticle
Aug 21, 2008Approval Vidaza Receives Expanded FDA Approval to Include Overall Survival in Higher-Risk MDS
Jan 30, 2007Approval Pharmion Corporation Announces FDA Approval of Vidaza NDASupplement for IV Administration
May 19, 2004Approval FDA Approves Vidaza for Myelodysplastic Syndromes (MDS)
Feb 23, 2004FDA Accepts Pharmion's New Drug Application for Filing and Grants Priority Review for Vidaza for the Treatment of Myelodysplastic Syndromes (MDS)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide